Clovis Oncology stock soars 40% in early trading on positive Phase III data
BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) said the top-line data of its Phase III trial showed that its flagship […]
Source: BizWest
Related Articles
BizWest celebrates 40 years covering business and recognizes 40 iconic leaders who inspired the region’s development.
View related stories: Click here to view the 40th Anniversary supplement. ‘Turnpike’ helps define how economy has changed Wood: Preserving…
Bankrupt Clovis faces delisting from Nasdaq
BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS), which filed for Chapter 11 bankruptcy protection Dec. 11, has received a delisting…
Economy sends conflicting signals
First the bad news: Interest rates are soaring. Inflation continues to climb. Gross domestic product is declining nationally and in…
Biotechnology boom
The COVID-19 pandemic — and its seemingly never-ending aftermath — has been a nightmare for commercial landlords of many different…
Clovis Oncology files Chapter 11, agrees to sell a drug asset
BOULDER and WILMINGTON, Delaware — Boulder-based Clovis Oncology Inc. (Nasdaq: CLVS) filed for Chapter 11 bankruptcy protection Sunday. Its filing…